UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 552

Sortiert nach

Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer

Breast cancer research and treatment, 2010-08, Vol.123 (1), p.9-24

2010

Volltextzugriff (PDF)

Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer

British journal of cancer, 2007-01, Vol.96 (1), p.104-109

2007

Volltextzugriff (PDF)

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial

Annals of oncology, 2019-11, Vol.30 (11), p.1776-1783

2019

Volltextzugriff (PDF)

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer

Annals of oncology, 2005-07, Vol.16 (7), p.1123-1132

2005

Volltextzugriff (PDF)

Comparison of quadrant-specific breast cancer incidence trends in the United States and England between 1975 and 2013

Cancer epidemiology, 2016-10, Vol.44, p.186-194

2016

Volltextzugriff (PDF)

Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials

British journal of cancer, 2012-10, Vol.107 (8), p.1257-1267

2012

Volltextzugriff (PDF)

Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial

British journal of cancer, 2013-10, Vol.109 (9), p.2453-2461

2013

Volltextzugriff (PDF)

Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity

Clinical oncology (Royal College of Radiologists (Great Britain)), 2023-06, Vol.35 (6), p.397-407

2023

Volltextzugriff (PDF)

NEAT: National Epirubicin Adjuvant Trial - toxicity, delivered dose intensity and quality of life

British journal of cancer, 2008-10, Vol.99 (8), p.1226-1231

2008

Volltextzugriff (PDF)

Physical activity and breast cancer outcome: A brief review of evidence, current practice and future direction

European journal of surgical oncology, 2010-12, Vol.36 (12), p.1139-1148

2010

Volltextzugriff (PDF)

A phase II clinical trial of gemcitabine and split dose cisplatin in advanced non-small cell lung cancer in an outpatient setting

Oncology reports, 2008-07, Vol.20 (1), p.233-237

2008

Volltextzugriff (PDF)

Monitoring the introduction of new drugs – Herceptin to cardiotoxicity

Clinical medicine (London, England), 2006-09, Vol.6 (5), p.478-481

2006

Volltextzugriff (PDF)

A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen

Cancer chemotherapy and pharmacology, 2004-04, Vol.53 (4), p.341-348

2004

Volltextzugriff (PDF)

Role of tyrosine kinase inhibitors in lung cancer

Anti-cancer agents in medicinal chemistry, 2009-06, Vol.9 (5), p.569

2009

Volltextzugriff (PDF)

Metastatic breast cancer response after Exemestane withdrawal: a case report

Breast (Edinburgh), 2004-02, Vol.13 (1), p.66-68

2004

Volltextzugriff (PDF)

Reply: Randomised studies with translational end points are required to further elucidate the prognostic and predictive value of CA IX

British journal of cancer, 2007-04, Vol.96 (8), p.1310-1310

2007

Volltextzugriff (PDF)

Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial

The Lancet (British edition), 2009-02, Vol.373 (9663), p.567-574

2009

Volltextzugriff (PDF)

A novel method for controlling the pepsin digestion of antibodies

Journal of immunological methods, 1993-01, Vol.157 (1), p.165-173

1993

Volltextzugriff (PDF)

Abstract P5-16-14: NOSTRA PRELIM: A non randomised pilot study designed to assess the ability of image guided core biopsies to detect residual disease in patients with early breast cancer who have received neoadjuvant chemotherapy to inform the design of a planned trial

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P5-P5-16-14

2017

Volltextzugriff (PDF)

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial

Annals of oncology, 2019-11, Vol.30 (11), p.1776

2019

Volltextzugriff (PDF)

Abstract P1-06-02: Comparative survival analysis of multiparametric tests in the TEAM pathology study: What to do when molecular tests disagree?

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-06-02

2018

Volltextzugriff (PDF)

Abstract P1-06-04: Simplified histological grading of breast carcinoma – potential for improved concordance and consistency in breast cancer grading?

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-06-04

2018

Volltextzugriff (PDF)

Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries

British journal of surgery, 2010-05, Vol.97 (5), p.671-679

2010

Volltextzugriff (PDF)

Abstract OT1-05-02: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in high clinical risk early breast cancer

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT1-05-02-OT1-05-02

2019

Volltextzugriff (PDF)

Site-specifically radioiodinated antibody for targeting tumors

Cancer research (Chicago, Ill.), 1990-02, Vol.50 (3), p.857s-861s

1990

Volltextzugriff (PDF)

1 – 25 von 552

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(507)
Mit Volltextzugriff
(483)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(19)
The Astrophysical Journal
(19)
Cancer Research
(17)
Nature
(14)
Resuscitation
(14)
The New England Journal Of Medicine
(14)
New England Journal Of Medicine/the new England Journal Of Medicine
(12)
Circulation
(11)
The Astrophysical Journal. Supplement Series
(10)
Science
(8)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer

Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer

Comparison of quadrant-specific breast cancer incidence trends in the United States and England between 1975 and 2013

Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials

Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial

Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity

NEAT: National Epirubicin Adjuvant Trial - toxicity, delivered dose intensity and quality of life

Physical activity and breast cancer outcome: A brief review of evidence, current practice and future direction

A phase II clinical trial of gemcitabine and split dose cisplatin in advanced non-small cell lung cancer in an outpatient setting

Monitoring the introduction of new drugs – Herceptin to cardiotoxicity

A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen

Role of tyrosine kinase inhibitors in lung cancer

Metastatic breast cancer response after Exemestane withdrawal: a case report

Reply: Randomised studies with translational end points are required to further elucidate the prognostic and predictive value of CA IX

Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial

A novel method for controlling the pepsin digestion of antibodies

Abstract P5-16-14: NOSTRA PRELIM: A non randomised pilot study designed to assess the ability of image guided core biopsies to detect residual disease in patients with early breast cancer who have received neoadjuvant chemotherapy to inform the design of a planned trial

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial

Abstract P1-06-02: Comparative survival analysis of multiparametric tests in the TEAM pathology study: What to do when molecular tests disagree?

Abstract P1-06-04: Simplified histological grading of breast carcinoma – potential for improved concordance and consistency in breast cancer grading?

Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries

Abstract OT1-05-02: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in high clinical risk early breast cancer

Site-specifically radioiodinated antibody for targeting tumors

Suchergebnisse filtern